Stockreport

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine months Preliminary RP2D established a [Read more]